Invention Grant
US09255279B2 Anaplastic lymphoma kinase (ALK) as an oncogene capable of transforming normal human cells
有权
间变淋巴瘤激酶（ALK）作为能够转化正常人细胞的致癌基因
- Patent Title: Anaplastic lymphoma kinase (ALK) as an oncogene capable of transforming normal human cells
- Patent Title (中): 间变淋巴瘤激酶（ALK）作为能够转化正常人细胞的致癌基因
-
Application No.: US14197829Application Date: 2014-03-05
-
Publication No.: US09255279B2Publication Date: 2016-02-09
- Inventor: Mariusz Wasik , James L. Riley , Qian Zhang , Fang Wei
- Applicant: The Trustees of the University of Pennsylvania
- Applicant Address: US PA Philadelphia
- Assignee: The Trustees of the University of Pennsylvania
- Current Assignee: The Trustees of the University of Pennsylvania
- Current Assignee Address: US PA Philadelphia
- Agency: Saul Ewing LLP
- Agent Kathryn Doyle
- Main IPC: C12N5/00
- IPC: C12N5/00 ; C12N5/071 ; C12N15/85 ; G01N33/50 ; C12N15/113
Abstract:
The present invention provides compositions and methods for transforming primary mammalian cells using an oncogenic form of ALK wherein the transformed cells display features of that of a corresponding tumor cell isolated from a cancer subject. The invention also provides a method for immortalizing normal CD4+ T lymphocytes with a lymphoma-characteristic form of ALK such as NPM-ALK.
Public/Granted literature
- US20150031856A1 Anaplastic Lymphoma Kinase (ALK) As An Oncogene Capable Of Transforming Normal Human Cells Public/Granted day:2015-01-29
Information query
